Pfizer / Antimicrobial-resistance fund, page-10

Yes, lwlinwel, but I hope they have skillful lawyers to make the agreements. I was looking at the Pfizer - BioNTech deal and in that Pfizer pays something upfront, then milestones as royalties, and then they share the geographic areas ( if I got this right). In the case of PBT2 everything will be more complex, many more antibiotics which PBT2 will be working with, many more pharmacy companies, and distribution is needed all over the world as is the case with Covid-19 vaccination. To me, it looks that there will be a complex hybrid solution, some pharmacy companies perhaps will have a direct license agreement with ATH ( the biggest as PFE, Novartis, and TEVA) and smaller perhaps are supported by the fund and all are limited to a specific antibiotic drug and even geographic area. Sounds complex and may be too difficult in the end.
So with each agreement first upfront payment, then milestones and royalties for 16 years. The reality is that tens of agreements are needed to get PBT2 sales possible all over the world unless a deal is made only with a single big pharma. Just to keep track of all agreements is a lot of work for ATH.
I have no info on what is happening in these possible negotiations but I only try to understand why it has taken over 9 months and still it looks like nothing has been achieved.